Vetter expands its footprint in Asia Pacific 'sweet spot'

13 Nov 2017

The pharmaceutical service provider will be better positioned to support local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.

Vetter has officially opened a new branch office in South Korea. The new office in Songdo is located within the biologics cluster, which is often referred to as a ‘sweet spot’ by the industry as it houses numerous prominent biopharmaceutical companies and service providers.

Vetter expands its footprint in Asia Pacific 'sweet spot'
Another ribbon cutting ceremony takes place for Vetter in the Asia Pacific region.

Strengthening its global footprint in the Asia Pacific (APAC) region has been an ongoing goal for Vetter. The company established its APAC hub in Singapore in 2014, and subsequently formed a Japanese subsidiary by opening an office in Tokyo in 2015. Although the pharmaceutical service provider had already been active in the South Korean market for years, the establishment of its own local branch office underlines the company’s commitment to the Asia Pacific market, particularly South Korea. With the new footprint, Vetter will be better positioned to support its existing South Korean business as well as that of new local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.

“Today is yet another milestone for our company. This new office will allow us to directly serve both local and global companies with South Korean market interests,” said Vetter Managing Director Peter Soelkner. “We are certain that our market presence and activities in this market will serve as an additional base and contribution for Vetter’s future global organic growth.”

Read More

Related tags

Market News

Related news

Spanish CDMO working ahead of EU serialisation deadline

Spanish CDMO working ahead of EU serialisation deadline

6 Dec 2018

Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

Read more 
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

5 Dec 2018

The financing will power the global commercial launch of the company's Fluidity One system.

Read more 
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

4 Dec 2018

The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

Read more 
India to have strongest global growth in 2019?

India to have strongest global growth in 2019?

4 Dec 2018

Main drivers cited as ‘high-growth domestic market’ and ‘expanding manufacturing exports’.

Read more 
Catalent to expand biologics packaging capabilities

Catalent to expand biologics packaging capabilities

3 Dec 2018

Company's $14 million investment follows twentieth commercial drug approval at Bloomington, Indiana site.

Read more 
Merck successfully divests Consumer Health

Merck successfully divests Consumer Health

2 Dec 2018

Closing of sale to Procter & Gamble at a cash purchase price of €3.4 billion completed.

Read more 
Digital manufacturing is a top priority for life sciences

Digital manufacturing is a top priority for life sciences

29 Nov 2018

Zenith Technology survey reveals that more than half of those surveyed believe that Industry 4.0 will drive the most change.

Read more 
NIH to evaluate effectiveness of male contraceptive skin gel

NIH to evaluate effectiveness of male contraceptive skin gel

28 Nov 2018

The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

Read more 
QPS expands US-based Phase I clinical trial capabilities

QPS expands US-based Phase I clinical trial capabilities

27 Nov 2018

Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

Read more 
Hikma announces injectable licensing agreement

Hikma announces injectable licensing agreement

27 Nov 2018

Company provided with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next 5 years.

Read more